SANA
NASDAQSana Biotechnology Inc.
Website
News25/Ratings12
News · 26 weeks35-50%
2025-10-262026-04-19
Mix2090d
- Insider9(45%)
- SEC Filings6(30%)
- Other3(15%)
- Leadership1(5%)
- Offering1(5%)
Latest news
25 items- SECSEC Form 424B5 filed by Sana Biotechnology Inc.424B5 - Sana Biotechnology, Inc. (0001770121) (Filer)
- SECSana Biotechnology Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Sana Biotechnology, Inc. (0001770121) (Filer)
- PRSana Biotechnology and Mayo Clinic Announce Strategic Collaboration Focused on Improving Care in Type 1 Diabetes and Accelerating Development of SC451Sana and Mayo Clinic to collaborate across multiple areas with goal of accelerating development of and access to potentially curative therapies for patients with type 1 diabetes Initial efforts will include processes and protocols to improve handling of and clinical care involving SC451, a cell replacement therapy being developed for patients with type 1 diabetes, with a system that can be utilized at Mayo Clinic facilities and other sites around the world Motivated by patient-centric values, collaboration includes Mayo equity investment in Sana SEATTLE and ROCHESTER, Minn., April 13, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the pos
- INSIDERSEC Form 4 filed by Bishop Hans Edgar4 - Sana Biotechnology, Inc. (0001770121) (Issuer)
- PRWhy Smart Money Is Shifting From Clinical Data to Manufacturing LinesIssued on behalf of Avaí Bio, Inc.USANewsGroup.com News CommentaryVANCOUVER, BC, April 6, 2026 /CNW/ -- The global cell therapy manufacturing market is on track to nearly double, from $7.17 billion in 2026 to over $14 billion by 2035[1]. The science has been proving itself for years. What most of these companies still lack is the production backbone to actually deliver at scale: GMP qualified facilities, traceable cell banks, and manufacturing processes that regulators will sign off on. The FDA accelerated the timeline in early 2026 by formalizing flexible manufacturing and quality control oversight for cell and gene therapies, clearing a path that had stalled the jump from clinical validati
- INSIDERSEC Form 3 filed by new insider Patel Dhavalkumar Dhirajlal3 - Sana Biotechnology, Inc. (0001770121) (Issuer)
- INSIDERPresident & CEO Harr Steve covered exercise/tax liability with 24,345 shares and converted options into 91,666 shares, increasing direct ownership by 0.85% to 7,944,251 units (SEC Form 4)4 - Sana Biotechnology, Inc. (0001770121) (Issuer)
- INSIDEROfficer Wyrick Susan D. converted options into 13,666 shares and covered exercise/tax liability with 4,387 shares, increasing direct ownership by 5% to 196,196 units (SEC Form 4)4 - Sana Biotechnology, Inc. (0001770121) (Issuer)
- INSIDERSEC Form 4 filed by Officer Wyrick Susan D.4 - Sana Biotechnology, Inc. (0001770121) (Issuer)
- INSIDERSEC Form 4 filed by President & CEO Harr Steve4 - Sana Biotechnology, Inc. (0001770121) (Issuer)
- INSIDEROfficer Wyrick Susan D. converted options into 1,525 shares and covered exercise/tax liability with 491 shares, increasing direct ownership by 0.56% to 186,917 units (SEC Form 4)4 - Sana Biotechnology, Inc. (0001770121) (Issuer)
- SECSEC Form S-3ASR filed by Sana Biotechnology Inc.S-3ASR - Sana Biotechnology, Inc. (0001770121) (Filer)
- SECSEC Form 10-K filed by Sana Biotechnology Inc.10-K - Sana Biotechnology, Inc. (0001770121) (Filer)
- SECSana Biotechnology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - Sana Biotechnology, Inc. (0001770121) (Filer)
- PRSana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business UpdatesShared 12-month clinical results of ongoing UP421 type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression are safe and well-tolerated, evade detection by the immune system, and continue to function one year post-transplant New England Journal of Medicine published positive 12-week clinical results of the UP421 type 1 diabetes study Incorporating the tested hypoimmune technology to develop SC451, a hypoimmune-modified, stem cell-derived therapy, as a one-time treatment for patients with type 1 diabetes, with a goal of normal blood glucose, with no insulin and no immunosuppression Made significant progress with SC451 across manufa
- PRSana Biotechnology to Present at March 2026 Investor ConferencesSEATTLE, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in March. The presentations will feature a business overview and update. Sana will present at the Cowen 46th Annual Health Care Conference at 1:10 p.m. ET on Monday, March 2, 2026.Sana will present at the Citizens Life Sciences Conference at 1:40 p.m. ET on Wednesday, March 11, 2026. The webcasts will be accessible on the Investor Relations page of Sana's website at https://sana.com/. A replay of each presentation will be available at the same
- INSIDERSEC Form 4 filed by EVP, Chief Financial Officer Piper Brian4 - Sana Biotechnology, Inc. (0001770121) (Issuer)
- INSIDERSEC Form 3 filed by new insider Piper Brian3 - Sana Biotechnology, Inc. (0001770121) (Issuer)
- SECSana Biotechnology Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Sana Biotechnology, Inc. (0001770121) (Filer)
- PRSana Biotechnology Appoints Brian Piper as Executive Vice President, Chief Financial OfficerSEATTLE, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced the appointment of Brian Piper as Executive Vice President, Chief Financial Officer. Mr. Piper brings to Sana a breadth of biopharmaceutical financial and operational expertise with over 25 years of experience in various positions in the industry. Mr. Piper was most recently CFO of Scorpion Therapeutics and its post-acquisition spin-off, Antares Therapeutics. "I am thrilled to welcome Brian to Sana and to our leadership team," said Steve Harr, President and Chief Executive Officer of Sana. "He brings deep exper
- SECSEC Form SCHEDULE 13G filed by Sana Biotechnology Inc.SCHEDULE 13G - Sana Biotechnology, Inc. (0001770121) (Subject)
- SECSana Biotechnology Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Sana Biotechnology, Inc. (0001770121) (Filer)
- PRSana Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare ConferenceSEATTLE, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 44th Annual J.P. Morgan Healthcare Conference at 9:45 a.m. PT on Wednesday, January 14, 2026. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer. The webcast will be accessible on the Investor Relations page of Sana's website at https://sana.com/. A replay of the presentation will be available at the same location for 30 days following the conference. About Sana BiotechnologySana Biotechnology, In
- INSIDERDirector Bishop Hans Edgar was granted 6,157 shares, increasing direct ownership by 0.11% to 5,840,740 units (SEC Form 4)4 - Sana Biotechnology, Inc. (0001770121) (Issuer)
- INSIDEROfficer Wyrick Susan D. converted options into 7,500 shares and covered exercise/tax liability with 2,407 shares, increasing direct ownership by 3% to 185,883 units (SEC Form 4)4 - Sana Biotechnology, Inc. (0001770121) (Issuer)